60 Degrees Pharma Proposes Reverse Split, Boosts Equity Plan

TL;DR

**SXTPW is doing a reverse stock split and boosting its equity plan – smells like a desperate move to stay listed and incentivize execs, watch out for dilution.**

AI Summary

60 Degrees Pharmaceuticals, Inc. (SXTPW) is holding its 2025 Annual Meeting on October 8, 2025, virtually via live audio webcast. Key proposals include the election of five directors, an amendment to the 2022 Equity Incentive Plan to increase shares available for issuance by 250,000, and a significant amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio ranging from 1:3 to 1:10. The company also seeks ratification of RBSM LLP as its independent auditor for fiscal year 2025 and approval for an adjournment proposal to solicit additional proxies if needed. The Board of Directors unanimously recommends a 'FOR' vote on all proposals, indicating a strategic push to potentially improve stock price and facilitate future equity-based compensation. The reverse stock split, in particular, suggests the company is addressing potential delisting concerns or aiming for a higher per-share valuation.

Why It Matters

This DEF 14A filing reveals 60 Degrees Pharmaceuticals' strategic moves to address its stock valuation and future capital needs. The proposed reverse stock split, ranging from 1:3 to 1:10, is a critical indicator for investors, often signaling efforts to meet exchange listing requirements or enhance stock appeal, but also carries risks of further price decline. Increasing the 2022 Equity Incentive Plan by 250,000 shares impacts employee and executive compensation, potentially diluting existing shareholders. For customers and the broader market, these financial maneuvers could stabilize the company, allowing it to continue its pharmaceutical development in a competitive landscape.

Risk Assessment

Risk Level: high — The proposed reverse stock split at a ratio of 1:3 to 1:10 indicates significant concern about the company's stock price, often a precursor to delisting or a last-ditch effort to attract institutional investors. Additionally, increasing the 2022 Equity Incentive Plan by 250,000 shares could lead to further dilution for existing shareholders, especially given the company's current outstanding shares of 4,104,469 as of August 26, 2025.

Analyst Insight

Investors should carefully evaluate the implications of the reverse stock split on their holdings and consider the potential for further dilution from the increased equity incentive plan. Monitor the stock's performance post-split and assess the company's ability to maintain a higher share price and achieve its strategic goals.

Key Numbers

• 250,000 shares — Increase in shares for 2022 Equity Incentive Plan (Proposed increase in common stock available for issuance)
• 1:3 to 1:10 — Reverse stock split ratio range (Proposed range for reverse stock split of common stock)
• 4,104,469 shares — Common stock outstanding (Total shares of common stock outstanding as of the Record Date, August 26, 2025)
• October 8, 2025 — Annual Meeting Date (Date of the 2025 Annual Meeting of Stockholders)
• August 26, 2025 — Record Date (Date for determining stockholders entitled to vote)
• 5 — Number of directors (Number of directors to be elected at the Annual Meeting)
• 12:00 p.m. Eastern Time — Annual Meeting Time (Scheduled start time for the virtual Annual Meeting)
• September 3, 2025 — Internet Availability Notice Mailing Date (Date the Notice of Internet Availability of Proxy Materials was mailed)
• September 5, 2025 — Deadline for Printed Materials Request (Last day to request a paper copy of proxy materials)
• 1025 Connecticut Avenue NW Suite 1000 — Company Address (Location of 60 Degrees Pharmaceuticals, Inc. executive offices)

Key Players & Entities

• 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant and subject of the DEF 14A filing
• Geoffrey Dow (person) — Chief Executive Officer, President, and Director
• Tyrone Miller (person) — Chief Financial Officer
• RBSM LLP (company) — Independent auditor for fiscal year ending December 31, 2025
• SEC (regulator) — Securities and Exchange Commission
• Washington, D.C. (location) — Location of company's executive offices
• October 8, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
• August 26, 2025 (date) — Record Date for stockholders entitled to vote
• 2022 Equity Incentive Plan (other) — Plan proposed for amendment to increase shares
• Certificate of Incorporation (other) — Document proposed for amendment to effect a reverse stock split

FAQ

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and stringent regulatory oversight. Companies often face intense competition from both established players and emerging biotechs. Trends include a focus on specialized therapies, advancements in biotechnology, and increasing pressure on drug pricing.

Regulatory Implications

As a pharmaceutical company, 60 Degrees Pharmaceuticals is subject to extensive regulation by bodies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing practices is critical. Any failure to adhere to these regulations can result in significant penalties, product recalls, and reputational damage.

What Investors Should Do

1. Review the proposed reverse stock split ratio (1:3 to 1:10) and its potential impact on share price and market perception.
2. Evaluate the rationale for increasing the share pool for the 2022 Equity Incentive Plan by 250,000 shares.
3. Consider the company's stated reasons for seeking adjournment powers.

Key Dates

• 2025-10-08: 2025 Annual Meeting of Stockholders — This is the date for the annual meeting where key proposals, including director elections and a reverse stock split, will be voted upon.
• 2025-08-26: Record Date — Establishes the list of shareholders eligible to vote at the Annual Meeting.
• 2025-09-03: Mailing of Notice of Internet Availability of Proxy Materials — Informs shareholders how to access proxy materials online, facilitating early review and voting.

Glossary

DEF 14A

A proxy statement filed with the SEC by publicly traded companies that are soliciting shareholder votes for an annual meeting. (This document contains the information shareholders need to make informed voting decisions on proposals presented at the annual meeting.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (The company is proposing a reverse stock split to potentially increase its stock price, address delisting concerns, or improve its market perception.)

Equity Incentive Plan

A plan that allows a company to grant stock options, restricted stock, or other equity-based awards to employees and directors as a form of compensation. (The company seeks to increase the number of shares available under its 2022 Equity Incentive Plan to facilitate future compensation and employee retention.)

Certificate of Incorporation

The foundational legal document filed with the state of incorporation that creates a corporation and outlines its basic structure and powers. (An amendment to this document is required to implement the proposed reverse stock split.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to examine its financial statements and provide an independent opinion on their fairness and accuracy. (Shareholders are asked to ratify the appointment of RBSM LLP as the company's auditor for fiscal year 2025.)

Year-Over-Year Comparison

This filing indicates a significant shift in strategic focus compared to previous periods, with the introduction of a reverse stock split proposal. While specific financial metrics for comparison are not detailed in this excerpt, the proposed equity plan amendment and reverse split suggest the company is actively seeking to improve its financial standing and market position, potentially in response to prior performance or market conditions.

Filing Documents

• ea0254708-def14a_60degrees.htm (DEF 14A) — 481KB
• image_001.jpg (GRAPHIC) — 14KB
• image_002.jpg (GRAPHIC) — 14KB
• image_003.jpg (GRAPHIC) — 315KB
• 0001213900-25-080878.txt ( ) — 955KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 18 DELINQUENT SECTION 16(A) REPORTS 20

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 21 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 23 PROPOSAL 2: APPROVAL OF AMENDMENT TO THE 2022 EQUITY INCENTIVE PLAN TO INCREASE TOTAL NUMBER OF AUTHORIZED SHARES BY 250,000 SHARES 24 PROPOSAL 3: APPROVAL OF AMENDMENT OF CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT AT A SPLIT RATIO OF 1:3 TO 1:10, INCLUSIVE, AS DETERMINED BY THE BOARD OF DIRECTORS IN ITS SOLE DISCRETION 30 PROPOSAL 4: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 35 PROPOSAL 5: APPROVAL OF THE ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IN THE EVENT THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE DIRECTOR ELCTION PROPOSAL, THE 2022 PLAN AMENDMENT PROPOSAL AND THE CERTIFICATE OF INCORPORATION AMENDMENT PROPOSAL 36 ADDITIONAL INFORMATION 37 i 60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 PROXY STATEMENT For Annual Meeting of Stockholders to Be Held on October 8, 2025 The Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (“60 Degrees Pharmaceuticals,” “60P,” “Company,” “we,” “us” or “our”), solicits the enclosed proxy for use at the 2024 Annual Meeting of Stockholders of the Company (“Annual Meeting”) to be held on October 8, 2025, only via live audio webcast over the telephone by following the instructions set forth here at “ Questions and Answers About the Meeting And Voting — How Do I Vote at the Annual Meeting? ” This proxy statement (“Proxy Statement”) and the accompanying Notice of Annual Meeting of Stockholders (the “Notice”) and form of proxy are first being made available to stockholders on or about August 26, 2025. We are furnishing proxy materials to o

View Full Filing

View this DEF 14A filing on SEC EDGAR